APTITUDE HEALTH®

EPICS

Conference Coverage: ESMO 2025 – Focus on Gastrointestinal (GI) Malignancies

November 6, 2025

Report Contents

EPICS

Content	Link
Meeting Snapshot	
Faculty Panel	
Meeting Agenda	
Key Insights and Strategic Recommendations	
Colorectal Cancer (CRC)	
Rectal Cancer	
Gastric, Esophageal, and Gastroesophageal Junction (GEJ) Cancers	
Pancreatic Cancer and Biliary Tract Cancer	
Hepatocellular Carcinoma (HCC)	

Meeting Snapshot: Conference Coverage – ESMO 2025: Focus on GI Malignancies

EPICS

A closed-door roundtable discussion focused on updates from ESMO 2025 was held virtually on **November 6, 2025**

GI cancer-specific discussions on latest research updates, therapeutic advances, and their application in clinical decision-making were led by **Tanios Bekaii-Saab, MD, FACP,** from Mayo Clinic Cancer Center Phoenix

The panel consisted of 6 key experts in GI cancers

- 4 from the US
- 2 from Europe

Insights report including postmeeting analyses and actionable recommendations

Panel of 4 US and 2 European GI Cancer Experts

EPICS

Nataliya Uboha, MD, PhD
University of Wisconsin–
Madison

Alan Venook, MD, FASCO
Helen Diller Family
Comprehensive Cancer Center

Wungki Park, MD
Memorial Sloan Kettering
Cancer Center

CHAIR
Tanios Bekaii-Saab, MD, FACP
Mayo Clinic Cancer Center
Phoenix

Dirk Arnold, MD, PhD
Asklepios Tumor Center Hamburg

Julien Taieb, MD, PhD
Georges Pompidou
European Hospital

APTITUDE HEALTH®

Meeting Agenda

EPICS

Time (PT)	Topic	Speaker/Moderator
8.30 AM – 8.35 AM (5 min)	**Welcome and Introductions**	Tanios Bekaii-Saab, MD, FACP
8.35 AM – 8.50 AM (15 min)	**Colorectal Cancer (CRC)**	Julien Taieb, MD, PhD
8.50 AM – 9.20 AM (30 min)	Discussion	All
9.20 AM – 9.25 AM (5 min)	Summary and Key Takeaways	Julien Taieb, MD, PhD
9.25 AM – 9.35 AM (10 min)	**Rectal Cancer**	Dirk Arnold, MD, PhD
9.35 AM – 9.45 AM (10 min)	Discussion	All
9.45 AM – 9.50 AM (5 min)	Summary and Key Takeaways	Dirk Arnold, MD, PhD
9.50 AM – 9.55 AM (5 min)	***Break***	
9.55 AM – 10.05 AM (10 min)	**Gastric, Esophageal, and Gastroesophageal Junction (GEJ) Cancers**	Nataliya Uboha, MD, PhD
10.05 AM – 10.20 AM (15 min)	Discussion	All
10.20 AM – 10.25 AM (5 min)	Summary and Key Takeaways	Nataliya Uboha, MD, PhD
10.25 AM – 10.35 AM (10 min)	**Pancreatic Cancer and Biliary Tract Cancer**	Wungki Park, MD
10.35 AM – 10.55 AM (20 min)	Discussion	All
10.55 AM – 11.00 AM (5 min)	Summary and Key Takeaways	Wungki Park, MD
11.00 AM – 11.10 AM (10 min)	**Hepatocellular Carcinoma (HCC)**	Alan Venook, MD, FASCO
11.10 AM – 11.25 AM (15 min)	Discussion	All
11.25 AM – 11.30 AM (5 min)	Summary and Key Takeaways	Alan Venook, MD, FASCO
11.30 AM	**Summary and Closing Remarks**	Tanios Bekaii-Saab, MD, FACP

APTITUDE HEALTH®

EPICS

Colorectal Cancer (CRC)

Conference Highlights Presented by
Julien Taieb, MD, PhD

Abstract Selection (1/3)

EPICS

Abstract Selection (2/3)

EPICS

Abstract Selection (3/3)

EPICS

Prognostic value of the Combined Analysis of Pathologists and Artificial Intelligence (CAPAI) in high-risk stage II–III colon cancer treated without chemotherapy: Interim report from a nationwide validation

Bakker MCE, et al. Abstract 726O

EPICS

Prognostic value of the Combined Analysis of Pathologists and Artificial Intelligence (CAPAI) in high-risk stage II–III colon cancer treated without chemotherapy: Interim report from a nationwide validation

Bakker MCE, et al. Abstract 726O

EPICS

APTITUDE HEALTH®

Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): New results from CheckMate 8HW

Lonardi S, et al. Abstract LBA29

EPICS

Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): New results from CheckMate 8HW

Lonardi S, et al. Abstract LBA29

EPICS



APTITUDE HEALTH®

Circulating tumor (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER

Kopetz S, et al. Abstract 729O

EPICS

APTITUDE HEALTH®

Circulating tumor (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER

EPICS

Kopetz S, et al. Abstract 729O

Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients with previously treated metastatic colorectal cancer: Primary overall survival analysis from the randomized, open-label, phase 3 STELLAR-303 study

EPICS

Saeed A, et al. Abstract LBA30

Zanzalintinib plus atezolizumab (zanza + atezo) vs regorafenib (rego) in patients with previously treated metastatic colorectal cancer: Primary overall survival analysis from the randomized, open-label, phase 3 STELLAR-303 study

EPICS

Saeed A, et al. Abstract LBA30

APTITUDE HEALTH®

EPICS

Colorectal Cancer (CRC)

Discussion

Colorectal Cancer (CRC)

EPICS

APTITUDE HEALTH®

Colorectal Cancer (CRC)

EPICS

APTITUDE HEALTH®

Colorectal Cancer (CRC)

EPICS

Colorectal Cancer (CRC)

EPICS

Colorectal Cancer (CRC)

EPICS

Colorectal Cancer (CRC)

EPICS

APTITUDE HEALTH®

Colorectal Cancer (CRC)

EPICS

APTITUDE HEALTH®

Colorectal Cancer (CRC)

EPICS

APTITUDE HEALTH®

Colorectal Cancer (CRC)

EPICS

Colorectal Cancer (CRC)

EPICS

Colorectal Cancer (CRC)

EPICS

APTITUDE HEALTH®

Colorectal Cancer (CRC)

EPICS

Colorectal Cancer (CRC)

EPICS

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Rectal Cancer

Conference Highlights Presented by
Dirk Arnold, MD, PhD

Abstract Selection

EPICS

Serplulimab combined with CapeOX and celecoxib as neoadjuvant therapy for proficient mismatch repair locally advanced mid-to-low rectal cancer (SCAR)

Ding K, et al. Abstract 786P

EPICS



APTITUDE HEALTH®

Serplulimab combined with CapeOX and celecoxib as neoadjuvant therapy for proficient mismatch repair locally advanced mid-to-low rectal cancer (SCAR)

Ding K, et al. Abstract 786P

EPICS



APTITUDE HEALTH®

Chemoradiotherapy followed by sequential tislelizumab (TIS) + CAPOX and TIS for organ preservation in low rectal cancer (RELIEVE-01): Primary results

EPICS

Tang W, et al. Abstract 741P







Chemoradiotherapy followed by sequential tislelizumab (TIS) + CAPOX and TIS for organ preservation in low rectal cancer (RELIEVE-01): Primary results

EPICS

Tang W, et al. Abstract 741P



APTITUDE HEALTH®

EPICS

Rectal Cancer

Discussion

Rectal Cancer

EPICS

APTITUDE HEALTH®

Rectal Cancer

EPICS

APTITUDE HEALTH®

Rectal Cancer

EPICS

APTITUDE HEALTH®

Rectal Cancer

EPICS

APTITUDE HEALTH®

EPICS

Gastric, Esophageal, and Gastroesophageal Junction (GEJ) Cancers

Conference Highlights Presented by
Nataliya Uboha, MD, PhD

Abstract Selection (1/3)

EPICS

Abstract Selection (2/3)

EPICS

Abstract Selection (3/3)

EPICS

Final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel in resectable G/GEJ adenocarcinoma

Tabernero J, et al. Abstract LBA81

EPICS

APTITUDE HEALTH®

Final overall survival and the association of pathological outcomes with event-free survival in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel in resectable G/GEJ adenocarcinoma

Tabernero J, et al. Abstract LBA81

EPICS

SKYSCRAPER-07: A phase III, randomised study of atezolizumab with or without tiragolumab in patients with unresectable esophageal squamous cell carcinoma that has not progressed following definitive concurrent chemoradiotherapy

Chau I, et al. Abstract 2094O

EPICS

APTITUDE HEALTH®

SKYSCRAPER-07: A phase III, randomised study of atezolizumab with or without tiragolumab in patients with unresectable esophageal squamous cell carcinoma that has not progressed following definitive concurrent chemoradiotherapy

Chau I, et al. Abstract 2094O

EPICS



RC118 (CLDN18.2-targeted ADC) combined with PD-1 blockade or RC148 (PD-1/VEGF bispecific antibody) for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (la/m G/GEJA)

Liu T, et al. Abstract LBA83

EPICS

APTITUDE HEALTH®

RC118 (CLDN18.2-targeted ADC) combined with PD-1 blockade or RC148 (PD-1/VEGF bispecific antibody) for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (la/m G/GEJA)

Liu T, et al. Abstract LBA83

EPICS



APTITUDE HEALTH®

EPICS

Gastric, Esophageal, and Gastroesophageal Junction (GEJ) Cancers

Discussion

Gastroesophageal Junction (GEJ) and Gastric Cancer

EPICS

Gastroesophageal Junction (GEJ) and Gastric Cancer

EPICS

Gastroesophageal Junction (GEJ) and Gastric Cancer

EPICS

Gastroesophageal Junction (GEJ) and Gastric Cancer

EPICS

Gastroesophageal Junction (GEJ) and Gastric Cancer

EPICS

Gastroesophageal Junction (GEJ) and Gastric Cancer

EPICS

Gastroesophageal Junction (GEJ) and Gastric Cancer

EPICS

Gastroesophageal Junction (GEJ) and Gastric Cancer

EPICS

Gastroesophageal Junction (GEJ) and Gastric Cancer

EPICS

Gastroesophageal Junction (GEJ) and Gastric Cancer

EPICS

APTITUDE HEALTH®

EPICS

Pancreatic Cancer and Biliary Tract Cancer

Conference Highlights Presented by
Wungki Park, MD

Abstract Selection (1/2)

EPICS

APTITUDE HEALTH®

Abstract Selection (2/2)

EPICS

VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)

Garcia-Carbonero R, et al. Abstract 2216MO

EPICS



VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)

Garcia-Carbonero R, et al. Abstract 2216MO

EPICS

APTITUDE HEALTH®

HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D mutant advanced pancreatic cancer: A phase Ib/II study

Wang L, et al. Abstract 2215O

EPICS

APTITUDE HEALTH®

HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D mutant advanced pancreatic cancer: A phase Ib/II study

Wang L, et al. Abstract 2215O

EPICS

APTITUDE HEALTH®

Dynamic circulating tumor DNA guided adjuvant therapy for biliary tract carcinoma: A prospective study (NCT06171321)

Wang J, et al. Abstract 96P

EPICS

APTITUDE HEALTH®

Dynamic circulating tumor DNA guided adjuvant therapy for biliary tract carcinoma: A prospective study (NCT06171321)

Wang J, et al. Abstract 96P

EPICS

APTITUDE HEALTH®

EPICS

Pancreatic Cancer and Biliary Tract Cancer

Discussion

Pancreatic Cancer and Biliary Tract Cancer

EPICS

Pancreatic Cancer and Biliary Tract Cancer

EPICS

Pancreatic Cancer and Biliary Tract Cancer

EPICS

Pancreatic Cancer and Biliary Tract Cancer

EPICS

Pancreatic Cancer and Biliary Tract Cancer

EPICS

Pancreatic Cancer and Biliary Tract Cancer

EPICS

Pancreatic Cancer and Biliary Tract Cancer

EPICS

Pancreatic Cancer and Biliary Tract Cancer

EPICS

APTITUDE HEALTH®

EPICS

Hepatocellular Carcinoma (HCC)

Conference Highlights Presented by
Alan Venook, MD, FASCO

Abstract Selection

EPICS

IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma

Galle PR, et al. Abstract LBA51

EPICS



APTITUDE HEALTH®

IKF-035/ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma

Galle PR, et al. Abstract LBA51

EPICS

APTITUDE HEALTH®

Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trial

Sun HC, et al. Abstract 1469MO

EPICS



Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): A multicenter, open-label, randomized phase III trial

Sun HC, et al. Abstract 1469MO

EPICS

APTITUDE HEALTH®

Long-term follow-up GDFATHER-01 trial: GDF-15 neutralization combined with nivolumab can enable deep, long-term remission in heavily pretreated, anti-PD1/-L1 relapsed/refractory non-squamous NSCLC, urothelial cancer, and HCC

Melero I, et al. Abstract 1513O

EPICS

APTITUDE HEALTH®

Long-term follow-up GDFATHER-01 trial: GDF-15 neutralization combined with nivolumab can enable deep, long-term remission in heavily pretreated, anti-PD1/-L1 relapsed/refractory non-squamous NSCLC, urothelial cancer, and HCC

Melero I, et al. Abstract 1513O

EPICS

APTITUDE HEALTH®

APTITUDE HEALTH®

EPICS

Hepatocellular Carcinoma (HCC)

Discussion

Hepatocellular Carcinoma (HCC)

EPICS

APTITUDE HEALTH®

Hepatocellular Carcinoma (HCC)

EPICS

APTITUDE HEALTH®

Hepatocellular Carcinoma (HCC)

EPICS

APTITUDE HEALTH®

Hepatocellular Carcinoma (HCC)

EPICS

APTITUDE HEALTH®

Hepatocellular Carcinoma (HCC)

EPICS

APTITUDE HEALTH®

US 5901-B Peachtree Dunwoody Road
Suite 415, Atlanta, GA 30328, US

EU Laan van Nieuw Oost-Indië 133 F
2593 BM The Hague, the Netherlands

UK 6th Floor, 2 Kingdom Street
London, W2 6BD, United Kingdom

aptitudehealth.com